A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
OHSU Knight Cancer Institute
Beth Israel Deaconess Medical Center
Dartmouth-Hitchcock Medical Center
Melbourne Health
Amgen
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Prelude Therapeutics
Bellicum Pharmaceuticals
Medigene AG
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Bellicum Pharmaceuticals
University of Pennsylvania
Case Comprehensive Cancer Center
Celgene
Celgene
University College, London
University of Maryland, Baltimore
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Celyad Oncology SA
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of California, San Francisco
Massachusetts General Hospital
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Massachusetts General Hospital
Benovus Bio, Inc.
Celgene
City of Hope Medical Center
4SC AG
Cellerant Therapeutics
Indiana University
Indiana University
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey